What increased confidence in Biogen’s latest Alzheimer’s drug means for Eli Lilly
Wall Street has a growing belief that US drug regulators will approve Biogen’s latest experimental Alzheimer’s treatment (BIIB) after detailed late-stage clinical trial data is released. It’s a development that may have positive implications for Eli Lilly (LLY) as the Club holding company studies a similar disease-targeting drug. Lecanemab – jointly developed by Biogen and …
What increased confidence in Biogen’s latest Alzheimer’s drug means for Eli Lilly Read More »